Kleferein’s 3-chloro-4-fluorophenyl-piperazine. It was created from the combination of two molecules, mCPP and pFPP. German scientist Burman, reading reviews from online forums about psychoactive substances, often read that simultaneous ingestion of pFPP and mCPP induces euphoria stronger than MDMA. He decided to check what effects will provide such phenylpiperazine containing both substituents from the mentioned compounds’. This idea turned out to be great. The substance, as expected, worked like a stronger version of MDMA.

Substance shows relatively low health damage. It was based on two metabolites of well-tested medicines:

  • pFPP is a metabolite of niaprazin [1]
  • mCPP is a metabolite of trazodone, nefazodone, etoperidone, enpiprazole, mepiprazole [2]

Kleferein effects are similar to these compounds. It affects the same receptors, it enters the same metabolic pathways. In case of poisoning caused by excessive consumption (which we do not wish to anyone), medical help is easy due to the detailed research that was carried out on phenylpiperazines [3,4,5,6].
    In modern pharmaceuticals and modern medicines, piperein skeleton has won with amphetamine skeleton. Was that by chance? No, the benefits of this solution far outweighed the negative effects. Why was it introduced so late? Contrary to first impression, synthesis is not easy. Everything that is good is made the hard way.

  1. Keane PE, Strolin Benedetti M, Dow J. The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain. Neuropharmacology. 1982 Feb;21(2):163-9.
  2. Elliott S (2011). “Current awareness of piperazines: pharmacology and toxicology”. Drug Test Anal3 (7–8): 430–8.
  3. Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF. Molecular pharmacology of niaprazine. Progress in Neuro-psychopharmacology and Biological Psychiatry. 1988;12(6):989-1001.
  4. Antia U, Tingle MD, Russell BR (July 2009). “Metabolic interactions with piperazine-based ‘party pill’ drugs”. The Journal of Pharmacy and Pharmacology61(7): 877–82.
  5. Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG (October 2007). “Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls”
  6. Hamik A, Peroutka SJ (1989). “1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain”. Biol. Psychiatry25 (5): 569–75.